VKTX
HealthcareViking Therapeutics, Inc.
$32.14
$-3.28 (-9.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Viking Therapeutics, Inc. is a biotechnology company within the healthcare sector. The company's market capitalization stands at $3.63 billion, indicating its substantial scale. With 50 employees, Viking operates on a relatively small staff compared to its market value. From a financial perspective, Viking has reported net income of -$237,394,000 over the trailing twelve months, resulting in zero gross margin, operating margin, and profit margin. The company's returns on equity and assets are -29.2% and -20.5%, respectively, reflecting significant losses. Its balance sheet shows $714.57 million in cash reserves and $755,000 in debt. The company's valuation is characterized by a negative forward P/E ratio of -8.64, indicating that the market's expectations for future earnings are currently below zero. The price to book ratio stands at 5.07. The lack of revenue growth and earnings growth data does not allow for an assessment of these metrics.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $3.63B
- P/E Ratio
- N/A
- 52-Week High
- $43.15
- 52-Week Low
- $18.92
- Avg Volume
- 3.60M
- Beta
- 0.70
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 50